Features and Factors Associated With Myeloid Neoplasms After Chimeric Antigen Receptor T-Cell Therapy

Menée aux Etats-Unis auprès de 120 témoins et 20 patients atteints d'une maladie lymphoproliférative traitée par immunothérapie à base de lymphocytes CAR-T ciblant CD19 (âge médian : 67 ans ; 60 % de femmes), cette étude identifie des facteurs de risque de néoplasme myéloïde lié au traitement

Résumé en anglais

Impressive clinical trial outcomes led to US Food and Drug Administration approval of chimeric antigen receptor T-cell therapy (CART) targeting CD19 for B-cell lymphoproliferative disorders (LPDs) and B-cell maturation antigen for multiple myeloma (MM). The most common CART toxic effect, immune effector cell–associated hematotoxicity (ICAHT), generally resolves by month 3. Myeloid neoplasms occurring after CART (post-CART MN) are also recognized outcomes but with short latency. To inform counseling, risk stratification, and potential surveillance strategies, we report updated incidence and factors associated with post-CART MN events.